Celecoxib impairs heart development via inhibiting cyclooxygenase-2 activity in zebrafish embryos

Anesthesiology

Volumn 114, Issue 2, 2011, Pages 391-400

  Xu, Dao Jie ^a   Bu, Ji Wen ^b   Gu, Shan Ye ^b   Xia, Yi Meng ^b   Du, Jiu Lin ^b   Wang, Ying Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL MYOSIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; CARDIAC MYOSIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; VERSICAN;

ARTICLE; BLOOD REGURGITATION; CONGENITAL HEART MALFORMATION; DEVELOPMENTAL STAGE; DOWNSTREAM PROCESSING; EMBRYO; HEART DEVELOPMENT; HEART FAILURE; IN SITU HYBRIDIZATION; IN VIVO STUDY; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; ZEBRA FISH;

EID: 79251616351     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182039f22     Document Type: Article

References (40)

1. Ostensen ME, Skomsvoll JF: Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother 2004; 5:571-80
2. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sorensen HT: Drug use in first pregnancy and lactation: A population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol 1999; 55:139-44
3. Flower RJ: The development of COX2 inhibitors. Nat Rev Drug Discov 2003; 2:179-91
4. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-80
5. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005; 365:475-81
6. McGrath P, Li CQ: Zebrafish: A predictive model for assessing drug-induced toxicity. Drug Discov Today 2008; 13:394-401
7. Scherz PJ, Huisken J, Sahai-Hernandez P, Stainier DY: Highspeed imaging of developing heart valves reveals interplay of morphogenesis and function. Development 2008; 135: 1179-87
8. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA: Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003; 107:1355-8
9. Zon LI, Peterson RT: In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005; 4:35-44
10. Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S: Zebrafish: An emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 2008; 154:1400-13
11. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF: Stages of embryonic development of the zebrafish. Dev Dyn 1995; 203:253-310
12. Yu PC, Gu SY, Bu JW, Du JL: TRPC1 is essential for in vivo angiogenesis in zebrafish. Circ Res 2010; 106:1221-32
13. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI: Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007; 447:1007-11
14. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P: Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005; 7:R422-35
15. Munkarah AR, Genhai Z, Morris R, Baker VV, Deppe G, Diamond MP, Saed GM: Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 2003; 88:429-33
16. Brown NA, Wolpert L: The development of handedness in left/right asymmetry. Development 1990; 109:1-9
17. Walsh EC, Stainier DY: UDP-glucose dehydrogenase required for cardiac valve formation in zebrafish. Science 2001; 293: 1670-3
18. Morton SU, Scherz PJ, Cordes KR, Ivey KN, Stainier DY, Srivastava D: microRNA-138 modulates cardiac patterning during embryonic development. Proc Natl Acad Sci USA 2008; 105:17830-5
19. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA: Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 2005; 193:771-7
20. Muth-Selbach US, Tegeder I, Brune K, Geisslinger G: Acetaminophen inhibits spinal prostaglandin E2 release after peripheral noxious stimulation. ANESTHESIOLOGY 1999; 91:231-9
21. Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. Faseb J 2008; 22:383-90
22. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113:1578-87
23. Forman JP, Stampfer MJ, Curhan GC: Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005; 46:500-7
24. Peng HC, Wang YH, Wen CC, Wang WH, Cheng CC, Chen YH: Nephrotoxicity assessments of acetaminophen during zebrafish embryogenesis. Comp Biochem Physiol C Toxicol Pharmacol 2010; 151:480-6
25. Ofori B, Oraichi D, Blais L, Rey E, Bérard A: Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006; 77:268-79
26. Takahashi Y, Roman C, Chemtob S, Tse MM, Lin E, Heymann MA, Clyman RI: Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol Regul Integr Comp Physiol 2000; 278:R1496 -505
27. Hao CM, Breyer MD: Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008; 70:357-77
28. Wang D, Patel VV, Ricciotti E, Zhou R, Levin MD, Gao E, Yu Z, Ferrari VA, Lu MM, Xu J, Zhang H, Hui Y, Cheng Y, Petrenko N, Yu Y, FitzGerald GA: Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA 2009; 106: 7548-52
29. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473-82
30. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197-208
31. Cha YI, Kim SH, Solnica-Krezel L, Dubois RN: Cyclooxygenase- 1 signaling is required for vascular tube formation during development. Dev Biol 2005; 282:274-83
32. Cha YI, Kim SH, Sepich D, Buchanan FG, Solnica-Krezel L, DuBois RN: Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation. Genes Dev 2006; 20:77-86
33. Yeh HC, Wang LH: Profiling of prostanoids in zebrafish embryonic development. Prostaglandins Leukot Essent Fatty Acids 2006; 75:397-402
34. Grosser T, Yusuff S, Cheskis E, Pack MA, FitzGerald GA: Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci USA 2002; 99:8418-23
35. Eisenberg LM, Markwald RR: Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 1995; 77: 1-6
36. Huang H, Zhang B, Hartenstein PA, Chen JN, Lin S: NXT2 is required for embryonic heart development in zebrafish. BMC Dev Biol 2005; 5:7
37. Glickman NS, Yelon D: Cardiac development in zebrafish: Coordination of form and function. Semin Cell Dev Biol 2002; 13:507-13
38. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. Faseb J 1998; 12:1063-73
39. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, Breyer RM: Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999; 5:217-20
40. Hawkey CJ: COX-2 inhibitors. Lancet 1999; 353:307-14